Trial Profile
Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Alisertib (Primary) ; Fulvestrant
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 16 Jan 2024 Planned End Date changed from 15 Dec 2023 to 31 Dec 2026.
- 14 Mar 2023 Results published in the Media Release
- 14 Mar 2023 According to a Puma Biotechnology media release, this trial was conducted through the Translational Breast Cancer Research Consortium.